Article info
PDFReview
Anti-CD20 therapies in pregnancy and breast feeding: a review and ABN guidelines
- Correspondence to Dr Ruth Dobson, Wolfson Institute of Population Health, Queen Mary University of London, London E1 4NS, UK; ruth.dobson{at}qmul.ac.uk
Citation
Anti-CD20 therapies in pregnancy and breast feeding: a review and ABN guidelines
Publication history
- Accepted June 13, 2022
- First published July 8, 2022.
Online issue publication
October 18, 2023
Article Versions
- Previous version (7 February 2023).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Rituximab in neurological disease: principles, evidence and practice
- Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders
- Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders
- Multiple sclerosis and the risk of infection: Association of British Neurologists consensus guideline
- Postpartum relapse risk in multiple sclerosis: a systematic review and meta-analysis
- A practical guide to the treatment of neuromyelitis optica
- Neurodegeneration in multiple sclerosis and neuromyelitis optica
- Is vaccine response to SARS-CoV-2 preserved after switching to anti-CD20 therapies in patients with multiple sclerosis or related disorders?
- Update on disease-modifying therapies for multiple sclerosis
- Neuromyelitis optica spectrum disorder: pregnancy-related attack and predictive risk factors